Sorrento Therapeutics Accounts Payable

Sorrento Therapeutics (SRNE) currently reports a accounts payable of $19M as of June 2023. That compares with $25M in the prior-year period — down 25.6% year over year. Use the charts on this page to explore Sorrento Therapeutics's accounts payable history and peer comparisons.

Sorrento Therapeutics's accounts payable decreased from $25M to $19M — a 25.6% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sorrento Therapeutics reported $19M in accounts payable as of June 2023. That compares with $25M in the prior-year period — down 25.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $19M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sorrento Therapeutics, and consider following SRNE for alerts when major investors trade the stock.

Sorrento Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $19M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SRNE with unrelated industries.